LTRN Stock — Lantern Pharma Inc

Lantern Pharma Inc (LTRN)

Updated October 16, 2026.

LTRN is a Stock. Total return is -95.5% over the past 6.3 years, 273.1 points behind SPY at 177.6%.

Lantern Pharma Inc. is an oncology-focused biopharmaceutical company developing a pipeline of cancer treatments, including drug candidates in clinical trials for non-small cell lung cancer, solid tumors, glioblastoma, and lymphomas, alongside preclinical programs and antibody drug conjugate therapeutics. The company also engages in strategic collaborations to advance cancer drug development using AI-driven approaches. As a clinical-stage biotech company, Lantern does not currently have an established distribution schedule.

LTRN performance versus SPY

Price and return data through 2026-10-16.

Total return is -95.5% over the past 6.3 years, 273.1 points behind SPY at 177.6%. Over the past year its total return — price change plus distributions reinvested — is -84.5%. Its deepest 1-year drawdown was 84.6%.

LTRN key facts

Asset type

Stock

Asset class

Equity

Inception date

06/11/2020

Distribution frequency

None

Last close

$0.67 (as of 2026-10-16)

Market cap

$9,982,939

Average volume

257810.0

Beta

2.323

Payout ratio

0.0%

EPS

$-1.54

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

LTRN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 84.6%.

Who may consider LTRN — and who may not

It is a weaker fit for investors who need monthly cash flow (LTRN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on LTRN

• All tickers starting with L

Tagged: Healthcare.

Frequently asked questions